Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
NCT05848687Phase 2Recruiting
- Start
- Nov 2023
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, scFv Fragments, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab and ziftomenib in acute lymphoblastic leukemia (ALL) and acute undifferentiated leukemia (AUL). Primary endpoint: Minimal Residual Disease. Started Nov 2023; status: recruiting.
02
Drugs
blinatumomabziftomenib
03
Conditions
acute lymphoblastic leukemia (ALL)acute undifferentiated leukemia (AUL)
Beyond the preview
Go deeper on NCT05848687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05848687.